These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20837981)

  • 21. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
    Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
    Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
    Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
    Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
    Sumner CR; Haynes VS; Teicher MH; Newcorn JH
    Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 32. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
    Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
    Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis.
    Van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
    Clin Psychol Rev; 2008 Jun; 28(5):783-800. PubMed ID: 18068284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atomoxetine in ADHD: caution].
    Karila L
    Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
    [No Abstract]   [Full Text] [Related]  

  • 35. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
    Starr HL; Kemner J
    J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.
    Bohnstedt BN; Kronenberger WG; Dunn DW; Giauque AL; Wood EA; Rembusch ME; Lafata D
    J Atten Disord; 2005 May; 8(4):153-9. PubMed ID: 16110045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
    J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.